Alteration of DNA methyltransferases by eribulin elicits broad DNA methylation changes with potential therapeutic implications for triple-negative breast cancer.
Meisam Bagheri, Min Kyung Lee, Kristen E Muller, Todd W Miller, Diwakar R Pattabiraman, Brock C Christensen.
Epigenomics. 2024 Mar;16(5):293-308. doi: 10.2217/epi-2023-0339. Epub 2024 Feb 15.

Estrogen Therapy Induces Receptor-Dependent DNA Damage Enhanced by PARP Inhibition in ER+ Breast Cancer.
Nicole A Traphagen, Gary N Schwartz, Steven Tau, Alyssa M Roberts, Amanda Jiang, Sarah R Hosford, Jonathan D Marotti, Abigail E Goen, Bianca A Romo, Anneka L Johnson, Emily-Claire K Duffy, Eugene Demidenko, Paul Heverly, Yaron Mosesson, Shannon M Soucy, Fred Kolling, Todd W Miller.
Clin Cancer Res. 2023 Sep 15;29(18):3717-3728. doi: 10.1158/1078-0432.CCR-23-0488.

Alteration of DNMT1/DNMT3A by eribulin elicits global DNA methylation changes with potential therapeutic implications for triple-negative breast cancer.
Meisam Bagheri, Min Kyung Lee, Kristen E Muller, Todd W Miller, Diwakar R Pattabiraman, Brock C Christensen.
bioRxiv [Preprint]. 2023 Jun 10:2023.06.09.544426. doi: 10.1101/2023.06.09.544426.

Alternating 17β-Estradiol and Aromatase Inhibitor Therapies Is Efficacious in Postmenopausal Women with Advanced Endocrine-Resistant ER+ Breast Cancer.
Gary N Schwartz, Peter A Kaufman, Karthik V Giridhar, Jonathan D Marotti, Mary D Chamberlin, Bradley A Arrick, Grace Makari-Judson, Matthew P Goetz, Shannon M Soucy, Fred Kolling, Eugene Demidenko, Todd W Miller.
Clin Cancer Res. 2023 Aug 1;29(15):2767-2773. doi: 10.1158/1078-0432.CCR-23-0112.

Pharmacological Induction of mesenchymal-epithelial transition chemosensitizes breast cancer cells and prevents metastatic progression.
Meisam Bagheri, Gadisti Aisha Mohamed, Mohammed Ashick Mohamed Saleem, Nevena B Ognjenovic, Hanxu Lu, Fred W Kolling, Owen M Wilkins, Subhadeep Das, Ian S La Croix, Shivashankar H Nagaraj, Kristen E Muller, Scott A Gerber, Todd W Miller, Diwakar R Pattabiraman.
bioRxiv [Preprint]. 2023 Apr 21:2023.04.19.537586. doi: 10.1101/2023.04.19.537586.

The role of cancer cell bioenergetics in dormancy and drug resistance.
Steven Tau, Todd W Miller.
Cancer Metastasis Rev. 2023 Mar;42(1):87-98. doi: 10.1007/s10555-023-10081-7. Epub 2023 Jan 25.

Alpelisib Efficacy without Cherry-PI3King Mutations.
Steven Tau, Todd W Miller.
Clin Cancer Res. 2023 Mar 14;29(6):989-990. doi: 10.1158/1078-0432.CCR-22-3411.

Tumour, whole-blood, plasma and tissue concentrations of metformin in lung cancer patients.
Joseph D Phillips, Darcy B Pooler, Dylan B Ness, Kayla Fay, Steven Tau, Eugene Demidenko, Riley A Hampsch, Lionel D Lewis, Todd W Miller.
Br J Clin Pharmacol. 2023 Mar;89(3):1027-1035. doi: 10.1111/bcp.15546. Epub 2022 Oct 12.

High estrogen receptor alpha activation confers resistance to estrogen deprivation and is required for therapeutic response to estrogen in breast cancer.
Nicole A Traphagen, Sarah R Hosford, Amanda Jiang, Jonathan D Marotti, Brooke L Brauer, Eugene Demidenko, Todd W Miller.
Oncogene. 2021 May;40(19):3408-3421. doi: 10.1038/s41388-021-01782-w. Epub 2021 Apr 19.

Pan-Cancer Transcriptional Models Predicting Chemosensitivity in Human Tumors.
Jason D Wells, Jacqueline R Griffin, Todd W Miller.
Cancer Inform. 2021 Mar 19;20:11769351211002494. doi: 10.1177/11769351211002494. eCollection 2021.

Phase Ib Study of the Oral Proteasome Inhibitor Ixazomib (MLN9708) and Fulvestrant in Advanced ER+ Breast Cancer Progressing on Fulvestrant.
Gary Schwartz, Kevin Shee, Bianca Romo, Jonathan Marotti, Alexei Kisselev, Lionel Lewis, Todd Miller.
Oncologist. 2021 Jun;26(6):467-e924. doi: 10.1002/onco.13733. Epub 2021 Mar 18.

Changes in Peripheral and Local Tumor Immunity after Neoadjuvant Chemotherapy Reshape Clinical Outcomes in Patients with Breast Cancer.
Margaret L Axelrod, Mellissa J Nixon, Paula I Gonzalez-Ericsson, Riley E Bergman, Mark A Pilkinton, Wyatt J McDonnell, Violeta Sanchez, Susan R Opalenik, Sherene Loi, Jing Zhou, Sean Mackay, Brent N Rexer, Vandana G Abramson, Valerie M Jansen, Simon Mallal, Joshua Donaldson, Sara M Tolaney, Ian E Krop, Ana C Garrido-Castro, Jonathan D Marotti, Kevin Shee, Todd W Miller, Melinda E Sanders, Ingrid A Mayer, Roberto Salgado, Justin M Balko.
Clin Cancer Res. 2020 Nov 1;26(21):5668-5681. doi: 10.1158/1078-0432.CCR-19-3685. Epub 2020 Aug 21.

Identification of Let-7f-5p as a novel biomarker of recurrence in non-muscle invasive bladder cancer.
Kevin Shee, John D Seigne, Margaret R Karagas, Carmen J Marsit, John W Hinds, Alan R Schned, Jason R Pettus, David A Armstrong, Todd W Miller, Angeline S Andrew.
Cancer Biomark. 2020;29(1):101-110. doi: 10.3233/CBM-191322.

Molecular matching and treatment strategies for advanced stage lung cancer at Dartmouth-Hitchcock Medical Center: A three-year review of a Molecular Tumor Board.
Erica B Bernhardt, Mary D Chamberlin, Ivan P Gorlov, Francine B de Abreu, Katarzyna J Bloch, Jason D Peterson, Gregory J Tsongalis, Keisuke Shirai, Konstantin H Dragnev, Todd W Miller, Laura J Tafe.
Pract Lab Med. 2020 Jun 12;21:e00174. doi: 10.1016/j.plabm.2020.e00174. eCollection 2020 Aug.

Plasma DNA as a "liquid biopsy" incompletely complements tumor biopsy for identification of mutations in a case series of four patients with oligometastatic breast cancer.
Mary D Chamberlin, Jason D Wells, Kevin Shee, Jennifer R Bean, Jonathan D Marotti, Wendy A Wells, Heidi W Trask, Fred W Kolling, Ananta Bhatt, Peter A Kaufman, Gary N Schwartz, John M Gemery, Nancy J McNulty, Michael J Tsapakos, Richard J Barth, Bradley A Arrick, Jiang Gui, Todd W Miller.
Breast Cancer Res Treat. 2020 Aug;182(3):665-677. doi: 10.1007/s10549-020-05714-2. Epub 2020 Jun 19.

AMPK Activation by Metformin Promotes Survival of Dormant ER<sup>+</sup> Breast Cancer Cells.
Riley A Hampsch, Jason D Wells, Nicole A Traphagen, Charlotte F McCleery, Jennifer L Fields, Kevin Shee, Lloye M Dillon, Darcy B Pooler, Lionel D Lewis, Eugene Demidenko, Yina H Huang, Jonathan D Marotti, Abigail E Goen, William B Kinlaw, Todd W Miller.
Clin Cancer Res. 2020 Jul 15;26(14):3707-3719. doi: 10.1158/1078-0432.CCR-20-0269. Epub 2020 Apr 22.

Endocytosis of very low-density lipoproteins: an unexpected mechanism for lipid acquisition by breast cancer cells.
Leslie E Lupien, Katarzyna Bloch, Jonas Dehairs, Nicole A Traphagen, William W Feng, Wilson L Davis, Thea Dennis, Johannes V Swinnen, Wendy A Wells, Nicole C Smits, Nancy B Kuemmerle, Todd W Miller, William B Kinlaw.
J Lipid Res. 2020 Feb;61(2):205-218. doi: 10.1194/jlr.RA119000327. Epub 2019 Dec 5.

Statistical determination of synergy based on Bliss definition of drugs independence.
Eugene Demidenko, Todd W Miller.
PLoS One. 2019 Nov 25;14(11):e0224137. doi: 10.1371/journal.pone.0224137. eCollection 2019.

Integrated pan-cancer gene expression and drug sensitivity analysis reveals SLFN11 mRNA as a solid tumor biomarker predictive of sensitivity to DNA-damaging chemotherapy.
Kevin Shee, Jason D Wells, Amanda Jiang, Todd W Miller.
PLoS One. 2019 Nov 4;14(11):e0224267. doi: 10.1371/journal.pone.0224267. eCollection 2019.

A Transcriptionally Definable Subgroup of Triple-Negative Breast and Ovarian Cancer Samples Shows Sensitivity to HSP90 Inhibition.
Kevin Shee, Jason D Wells, Matthew Ung, Riley A Hampsch, Nicole A Traphagen, Wei Yang, Stephanie C Liu, Megan A Zeldenrust, Liewei Wang, Krishna R Kalari, Jia Yu, Judy C Boughey, Eugene Demidenko, Arminja N Kettenbach, Chao Cheng, Matthew P Goetz, Todd W Miller.
Clin Cancer Res. 2020 Jan 1;26(1):159-170. doi: 10.1158/1078-0432.CCR-18-2213. Epub 2019 Sep 26.

Tumor pharmacokinetics and pharmacodynamics of the CDK4/6 inhibitor ribociclib in patients with recurrent glioblastoma.
Todd W Miller, Nicole A Traphagen, Jing Li, Lionel D Lewis, Beatriz Lopes, Ashok Asthagiri, Johanna Loomba, Jenny De Jong, David Schiff, Sohil H Patel, Benjamin W Purow, Camilo E Fadul.
J Neurooncol. 2019 Sep;144(3):563-572. doi: 10.1007/s11060-019-03258-0. Epub 2019 Aug 9.

Estrogen therapy induces an unfolded protein response to drive cell death in ER+ breast cancer.
Sarah R Hosford, Kevin Shee, Jason D Wells, Nicole A Traphagen, Jennifer L Fields, Riley A Hampsch, Arminja N Kettenbach, Eugene Demidenko, Todd W Miller.
Mol Oncol. 2019 Aug;13(8):1778-1794. doi: 10.1002/1878-0261.12528. Epub 2019 Jul 9.

Membrane-initiated estrogen signaling: oncogenic or impotent?.
Todd W Miller.
Expert Rev Endocrinol Metab. 2012 Jul;7(4):411-413. doi: 10.1586/eem.12.26.

Molecular and epigenetic profiles of BRCA1-like hormone-receptor-positive breast tumors identified with development and application of a copy-number-based classifier.
Youdinghuan Chen, Yue Wang, Lucas A Salas, Todd W Miller, Kenneth Mark, Jonathan D Marotti, Arminja N Kettenbach, Chao Cheng, Brock C Christensen.
Breast Cancer Res. 2019 Jan 25;21(1):14. doi: 10.1186/s13058-018-1090-z.

Ductal Carcinoma in Situ Biomarkers in a Precision Medicine Era: Current and Future Molecular-Based Testing.
Kevin Shee, Kristen E Muller, Jonathan Marotti, Todd W Miller, Wendy A Wells, Gregory J Tsongalis.
Am J Pathol. 2019 May;189(5):956-965. doi: 10.1016/j.ajpath.2018.08.020. Epub 2018 Oct 29.

Cytokine sensitivity screening highlights BMP4 pathway signaling as a therapeutic opportunity in ER<sup>+</sup> breast cancer.
Kevin Shee, Amanda Jiang, Frederick S Varn, Stephanie Liu, Nicole A Traphagen, Philip Owens, Cynthia X Ma, Jeremy Hoog, Chao Cheng, Todd R Golub, Ravid Straussman, Todd W Miller.
FASEB J. 2019 Feb;33(2):1644-1657. doi: 10.1096/fj.201801241R. Epub 2018 Aug 30.

Estrogen receptor alpha drives mTORC1 inhibitor-induced feedback activation of PI3K/AKT in ER+ breast cancer.
Wei Yang, Gary N Schwartz, Jonathan D Marotti, Vivian Chen, Nicole A Traphagen, Jiang Gui, Todd W Miller.
Oncotarget. 2018 Jan 15;9(10):8810-8822. doi: 10.18632/oncotarget.24256. eCollection 2018 Feb 6.

Coamplification of <em>miR-4728</em> protects <em>HER2</em>-amplified breast cancers from targeted therapy.
Konstantinos V Floros, Timothy L Lochmann, Bin Hu, Carles Monterrubio, Mark T Hughes, Jason D Wells, Cristina Bernadó Morales, Maninderjit S Ghotra, Carlotta Costa, Andrew J Souers, Sosipatros A Boikos, Joel D Leverson, Ming Tan, Violeta Serra, Jennifer E Koblinski, Joaquin Arribas, Aleix Prat, Laia Paré, Todd W Miller, Mikhail G Dozmorov, Hisashi Harada, Brad E Windle, Maurizio Scaltriti, Anthony C Faber.
Proc Natl Acad Sci U S A. 2018 Mar 13;115(11):E2594-E2603. doi: 10.1073/pnas.1717820115. Epub 2018 Feb 23.

Therapeutically targeting tumor microenvironment-mediated drug resistance in estrogen receptor-positive breast cancer.
Kevin Shee, Wei Yang, John W Hinds, Riley A Hampsch, Frederick S Varn, Nicole A Traphagen, Kishan Patel, Chao Cheng, Nicole P Jenkins, Arminja N Kettenbach, Eugene Demidenko, Philip Owens, Anthony C Faber, Todd R Golub, Ravid Straussman, Todd W Miller.
J Exp Med. 2018 Mar 5;215(3):895-910. doi: 10.1084/jem.20171818. Epub 2018 Feb 7.

Trailblazing Precision Oncology for Rare Tumor Subtypes.
Kevin Shee, Todd W Miller.
Oncologist. 2018 Feb;23(2):143-144. doi: 10.1634/theoncologist.2017-0494. Epub 2017 Nov 20.

Autophagy promotes escape from phosphatidylinositol 3-kinase inhibition in estrogen receptor-positive breast cancer.
Wei Yang, Sarah R Hosford, Nicole A Traphagen, Kevin Shee, Eugene Demidenko, Stephanie Liu, Todd W Miller.
FASEB J. 2018 Mar;32(3):1222-1235. doi: 10.1096/fj.201700477R. Epub 2018 Jan 3.

P-Rex1 Expression in Invasive Breast Cancer in relation to Receptor Status and Distant Metastatic Site.
Jonathan D Marotti, Kristen E Muller, Laura J Tafe, Eugene Demidenko, Todd W Miller.
Int J Breast Cancer. 2017;2017:4537532. doi: 10.1155/2017/4537532. Epub 2017 Jun 15.

Therapeutic sensitivity to Rac GTPase inhibition requires consequential suppression of mTORC1, AKT, and MEK signaling in breast cancer.
Riley A Hampsch, Kevin Shee, Darcy Bates, Lionel D Lewis, Laurent Désiré, Bertrand Leblond, Eugene Demidenko, Kurtis Stefan, Yina H Huang, Todd W Miller.
Oncotarget. 2017 Mar 28;8(13):21806-21817. doi: 10.18632/oncotarget.15586.

Maximizing the Benefit-Cost Ratio of Anthracyclines in Metastatic Breast Cancer: Case Report of a Patient with a Complete Response to High-Dose Doxorubicin.
Kevin Shee, Alan T Kono, Susan P D'Anna, Mark A Seltzer, Xiaoying Lu, Todd W Miller, Mary D Chamberlin.
Case Rep Oncol. 2016 Dec 8;9(3):840-846. doi: 10.1159/000453608. eCollection 2016 Sep-Dec.

Combined Inhibition of Both p110α and p110β Isoforms of Phosphatidylinositol 3-Kinase Is Required for Sustained Therapeutic Effect in PTEN-Deficient, ER<sup>+</sup> Breast Cancer.
Sarah R Hosford, Lloye M Dillon, Stephanie J Bouley, Rachele Rosati, Wei Yang, Vivian S Chen, Eugene Demidenko, Rocco P Morra, Todd W Miller.
Clin Cancer Res. 2017 Jun 1;23(11):2795-2805. doi: 10.1158/1078-0432.CCR-15-2764. Epub 2016 Nov 30.

Application of RNAi-induced gene expression profiles for prognostic prediction in breast cancer.
Yue Wang, Kenneth M K Mark, Matthew H Ung, Arminja Kettenbach, Todd Miller, Wei Xu, Wenqing Cheng, Tian Xia, Chao Cheng.
Genome Med. 2016 Oct 27;8(1):114. doi: 10.1186/s13073-016-0363-3.

The PREX1/Rac signaling axis: Potential as a biomarker and therapeutic target in breast cancer.
Lloye M Dillon, Todd W Miller.
Mol Cell Oncol. 2015 Apr 30;2(3):e996016. doi: 10.1080/23723556.2014.996016. eCollection 2015 Jul-Sep.

Clinical Implementation of Novel Targeted Therapeutics in Advanced Breast Cancer.
Mary D Chamberlin, Erica B Bernhardt, Todd W Miller.
J Cell Biochem. 2016 Nov;117(11):2454-63. doi: 10.1002/jcb.25590. Epub 2016 Jun 3.

Targeted next-generation sequencing detects a high frequency of potentially actionable mutations in metastatic breast cancers.
Kristen E Muller, Jonathan D Marotti, Francine B de Abreu, Jason D Peterson, Todd W Miller, Mary D Chamberlin, Gregory J Tsongalis, Laura J Tafe.
Exp Mol Pathol. 2016 Jun;100(3):421-5. doi: 10.1016/j.yexmp.2016.04.002. Epub 2016 Apr 16.

Strategically Timing Inhibition of Phosphatidylinositol 3-Kinase to Maximize Therapeutic Index in Estrogen Receptor Alpha-Positive, PIK3CA-Mutant Breast Cancer.
Wei Yang, Sarah R Hosford, Lloye M Dillon, Kevin Shee, Stephanie C Liu, Jennifer R Bean, Laurent Salphati, Jodie Pang, Xiaolin Zhang, Michelle A Nannini, Eugene Demidenko, Darcy Bates, Lionel D Lewis, Jonathan D Marotti, Alan R Eastman, Todd W Miller.
Clin Cancer Res. 2016 May 1;22(9):2250-60. doi: 10.1158/1078-0432.CCR-15-2276. Epub 2016 Jan 5.

Implementation of a Molecular Tumor Board: The Impact on Treatment Decisions for 35 Patients Evaluated at Dartmouth-Hitchcock Medical Center.
Laura J Tafe, Ivan P Gorlov, Francine B de Abreu, Joel A Lefferts, Xiaoying Liu, Jason R Pettus, Jonathan D Marotti, Kasia J Bloch, Vincent A Memoli, Arief A Suriawinata, Konstantin H Dragnev, Camilo E Fadul, Gary N Schwartz, Clinton R Morgan, Britt M Holderness, Jason D Peterson, Gregory J Tsongalis, Todd W Miller, Mary D Chamberlin.
Oncologist. 2015 Sep;20(9):1011-8. doi: 10.1634/theoncologist.2015-0097. Epub 2015 Jul 23.

The PI3K/mTOR dual inhibitor P7170 demonstrates potent activity against endocrine-sensitive and endocrine-resistant ER+ breast cancer.
Jennifer R Bean, Sarah R Hosford, Lynn K Symonds, Philip Owens, Lloye M Dillon, Wei Yang, Kevin Shee, Gary N Schwartz, Jonathan D Marotti, Kristen E Muller, Kari M Rosenkranz, Richard J Barth, Vivian S Chen, Veena R Agarwal, Todd W Miller.
Breast Cancer Res Treat. 2015 Jan;149(1):69-79. doi: 10.1007/s10549-014-3201-6. Epub 2014 Dec 10.

Estrogen receptor alpha and androgen receptor are commonly expressed in well-differentiated liposarcoma.
Davis R Ingram, Lloye M Dillon, Dina Chelouche Lev, Alexander Lazar, Elizabeth G Demicco, Burton L Eisenberg, Todd W Miller.
BMC Clin Pathol. 2014 Oct 22;14:42. doi: 10.1186/1472-6890-14-42. eCollection 2014.

Clinical potential of novel therapeutic targets in breast cancer: CDK4/6, Src, JAK/STAT, PARP, HDAC, and PI3K/AKT/mTOR pathways.
Sarah R Hosford, Todd W Miller.
Pharmgenomics Pers Med. 2014 Aug 6;7:203-15. doi: 10.2147/PGPM.S52762. eCollection 2014.

Targeting tyrosine-kinases and estrogen receptor abrogates resistance to endocrine therapy in breast cancer.
Shuying Liu, Xiaolong Meng, Huiqin Chen, Wenbin Liu, Todd Miller, Mandi Murph, Yiling Lu, Fan Zhang, Mihai Gagea, Carlos L Arteaga, Gordon B Mills, Funda Meric-Bernstam, Ana M González-Angulo.
Oncotarget. 2014 Oct 15;5(19):9049-64. doi: 10.18632/oncotarget.2022.

Therapeutic targeting of cancers with loss of PTEN function.
Lloye M Dillon, Todd W Miller.
Curr Drug Targets. 2014 Jan;15(1):65-79. doi: 10.2174/1389450114666140106100909.

Managing breast cancers with low estrogen receptor and HER2 by drugging both.
Todd W Miller.
Clin Cancer Res. 2014 Feb 1;20(3):528-30. doi: 10.1158/1078-0432.CCR-13-2994. Epub 2013 Dec 18.

Activation of MAPK pathways due to DUSP4 loss promotes cancer stem cell-like phenotypes in basal-like breast cancer.
Justin M Balko, Luis J Schwarz, Neil E Bhola, Richard Kurupi, Phillip Owens, Todd W Miller, Henry Gómez, Rebecca S Cook, Carlos L Arteaga.
Cancer Res. 2013 Oct 15;73(20):6346-58. doi: 10.1158/0008-5472.CAN-13-1385. Epub 2013 Aug 21.

Endocrine resistance: what do we know?.
Todd W Miller.
Am Soc Clin Oncol Educ Book. 2013. doi: 10.14694/EdBook_AM.2013.33.e37.

Abrogating endocrine resistance by targeting ERα and PI3K in breast cancer.
Emily M Fox, Carlos L Arteaga, Todd W Miller.
Front Oncol. 2012 Oct 16;2:145. doi: 10.3389/fonc.2012.00145. eCollection 2012.

Discordant cellular response to presurgical letrozole in bilateral synchronous ER+ breast cancers with a KRAS mutation or FGFR1 gene amplification.
Justin M Balko, Ingrid A Mayer, Melinda E Sanders, Todd W Miller, Maria G Kuba, Ingrid M Meszoely, Nikhil Wagle, Levi A Garraway, Carlos L Arteaga.
Mol Cancer Ther. 2012 Oct;11(10):2301-5. doi: 10.1158/1535-7163.MCT-12-0511. Epub 2012 Aug 9.

Profiling of residual breast cancers after neoadjuvant chemotherapy identifies DUSP4 deficiency as a mechanism of drug resistance.
Justin M Balko, Rebecca S Cook, David B Vaught, María G Kuba, Todd W Miller, Neil E Bhola, Melinda E Sanders, Nara M Granja-Ingram, J Joshua Smith, Ingrid M Meszoely, Janine Salter, Mitch Dowsett, Katherine Stemke-Hale, Ana M González-Angulo, Gordon B Mills, Joseph A Pinto, Henry L Gómez, Carlos L Arteaga.
Nat Med. 2012 Jul;18(7):1052-9. doi: 10.1038/nm.2795.

The receptor tyrosine kinase ErbB3 maintains the balance between luminal and basal breast epithelium.
Justin M Balko, Todd W Miller, Meghan M Morrison, Katherine Hutchinson, Christian Young, Cammie Rinehart, Violeta Sánchez, David Jee, Kornelia Polyak, Aleix Prat, Charles M Perou, Carlos L Arteaga, Rebecca S Cook.
Proc Natl Acad Sci U S A. 2012 Jan 3;109(1):221-6. doi: 10.1073/pnas.1115802109. Epub 2011 Dec 16.

Mutations in the phosphatidylinositol 3-kinase pathway: role in tumor progression and therapeutic implications in breast cancer.
Todd W Miller, Brent N Rexer, Joan T Garrett, Carlos L Arteaga.
Breast Cancer Res. 2011;13(6):224. doi: 10.1186/bcr3039. Epub 2011 Nov 1.

ERα-dependent E2F transcription can mediate resistance to estrogen deprivation in human breast cancer.
Todd W Miller, Justin M Balko, Emily M Fox, Zara Ghazoui, Anita Dunbier, Helen Anderson, Mitch Dowsett, Aixiang Jiang, R Adam Smith, Sauveur-Michel Maira, H Charles Manning, Ana M González-Angulo, Gordon B Mills, Catherine Higham, Siprachanh Chanthaphaychith, Maria G Kuba, William R Miller, Yu Shyr, Carlos L Arteaga.
Cancer Discov. 2011 Sep;1(4):338-51. doi: 10.1158/2159-8290.CD-11-0101. Epub 2011 Jul 20.

Phosphatidylinositol 3-kinase and antiestrogen resistance in breast cancer.
Todd W Miller, Justin M Balko, Carlos L Arteaga.
J Clin Oncol. 2011 Nov 20;29(33):4452-61. doi: 10.1200/JCO.2010.34.4879. Epub 2011 Oct 17.

A kinome-wide screen identifies the insulin/IGF-I receptor pathway as a mechanism of escape from hormone dependence in breast cancer.
Emily M Fox, Todd W Miller, Justin M Balko, Maria G Kuba, Violeta Sánchez, R Adam Smith, Shuying Liu, Ana María González-Angulo, Gordon B Mills, Fei Ye, Yu Shyr, H Charles Manning, Elizabeth Buck, Carlos L Arteaga.
Cancer Res. 2011 Nov 1;71(21):6773-84. doi: 10.1158/0008-5472.CAN-11-1295. Epub 2011 Sep 9.

A gene expression signature from human breast cancer cells with acquired hormone independence identifies MYC as a mediator of antiestrogen resistance.
Todd W Miller, Justin M Balko, Zara Ghazoui, Anita Dunbier, Helen Anderson, Mitch Dowsett, Ana M González-Angulo, Gordon B Mills, William R Miller, Huiyun Wu, Yu Shyr, Carlos L Arteaga.
Clin Cancer Res. 2011 Apr 1;17(7):2024-34. doi: 10.1158/1078-0432.CCR-10-2567. Epub 2011 Feb 23.

Hyperactivation of phosphatidylinositol-3 kinase promotes escape from hormone dependence in estrogen receptor-positive human breast cancer.
Todd W Miller, Bryan T Hennessy, Ana M González-Angulo, Emily M Fox, Gordon B Mills, Heidi Chen, Catherine Higham, Carlos García-Echeverría, Yu Shyr, Carlos L Arteaga.
J Clin Invest. 2010 Jul;120(7):2406-13. doi: 10.1172/JCI41680. Epub 2010 Jun 7.

Inhibition of mammalian target of rapamycin is required for optimal antitumor effect of HER2 inhibitors against HER2-overexpressing cancer cells.
Todd W Miller, James T Forbes, Chirayu Shah, Shelby K Wyatt, H Charles Manning, Maria G Olivares, Violeta Sanchez, Teresa C Dugger, Nara de Matos Granja, Archana Narasanna, Rebecca S Cook, J Phillip Kennedy, Craig W Lindsley, Carlos L Arteaga.
Clin Cancer Res. 2009 Dec 1;15(23):7266-76. doi: 10.1158/1078-0432.CCR-09-1665. Epub 2009 Nov 24.

Imaging biomarkers predict response to anti-HER2 (ErbB2) therapy in preclinical models of breast cancer.
Chirayu Shah, Todd W Miller, Shelby K Wyatt, Eliot T McKinley, Maria Graciela Olivares, Violeta Sanchez, Donald D Nolting, Jason R Buck, Ping Zhao, M Sib Ansari, Ronald M Baldwin, John C Gore, Rachel Schiff, Carlos L Arteaga, H Charles Manning.
Clin Cancer Res. 2009 Jul 15;15(14):4712-21. doi: 10.1158/1078-0432.CCR-08-2635. Epub 2009 Jul 7.

Loss of Phosphatase and Tensin homologue deleted on chromosome 10 engages ErbB3 and insulin-like growth factor-I receptor signaling to promote antiestrogen resistance in breast cancer.
Todd W Miller, Marianela Pérez-Torres, Archana Narasanna, Marta Guix, Olle Stål, Gizeh Pérez-Tenorio, Ana M Gonzalez-Angulo, Bryan T Hennessy, Gordon B Mills, J Phillip Kennedy, Craig W Lindsley, Carlos L Arteaga.
Cancer Res. 2009 May 15;69(10):4192-201. doi: 10.1158/0008-5472.CAN-09-0042. Epub 2009 May 12.

Aromatase is phosphorylated in situ at serine-118.
Todd W Miller, Incheol Shin, Norio Kagawa, Dean B Evans, Michael R Waterman, Carlos L Arteaga.
J Steroid Biochem Mol Biol. 2008 Nov;112(1-3):95-101. doi: 10.1016/j.jsbmb.2008.09.001. Epub 2008 Sep 4.

ErbB receptor signaling and therapeutic resistance to aromatase inhibitors.
Incheol Shin, Todd Miller, Carlos L Arteaga.
Clin Cancer Res. 2006 Feb 1;12(3 Pt 2):1008s-1012s. doi: 10.1158/1078-0432.CCR-05-2352.

Suppression of Huntington's disease pathology in Drosophila by human single-chain Fv antibodies.
William J Wolfgang, Todd W Miller, Jack M Webster, James S Huston, Leslie M Thompson, J Lawrence Marsh, Anne Messer.
Proc Natl Acad Sci U S A. 2005 Aug 9;102(32):11563-8. doi: 10.1073/pnas.0505321102. Epub 2005 Aug 1.

Intrabody applications in neurological disorders: progress and future prospects.
Todd W Miller, Anne Messer.
Mol Ther. 2005 Sep;12(3):394-401. doi: 10.1016/j.ymthe.2005.04.003.

A human single-chain Fv intrabody preferentially targets amino-terminal Huntingtin's fragments in striatal models of Huntington's disease.
Todd W Miller, Chun Zhou, Silvia Gines, Marcy E MacDonald, Nicholas D Mazarakis, Gillian P Bates, James S Huston, Anne Messer.
Neurobiol Dis. 2005 Jun-Jul;19(1-2):47-56. doi: 10.1016/j.nbd.2004.11.003.